Paralytic subileus as an adverse effect of amino acid-based nephroprotection in a patient undergoing peptide receptor radionuclide therapy.
Peptide receptor radionuclide therapy is routinely used for neuroendocrine tumors. To prevent radiopeptide retention at the proximal tubule of the kidney, positively charged amino are coinfused. However, hyperkalemia (>5.0 mmol/L) in more than three fourth of patients has been reported. In our case, the patient experienced acute hyperkalemia with blood values greater than 7.0 mmol/L with gastroparesis and subileus.